BMJ case reportsHumansSpondylitisAnkylosingAntibodiesMonoclonal
Treatment experience with secukinumab in two patients with ankylosing spondylitis and concomitant active tuberculosis.
Fatih Albayrak, Nurcihan Y Savaş, Melis Mutlu, Zeynel A Sayiner, Bunyamin Kisacik
Published: 202510.1136/bcr-2025-265465
Abstract
Patients with ankylosing spondylitis (AS) may require biological therapy, particularly tumour necrosis factor (TNF) inhibitors, which are effective but increase the risk of tuberculosis (TB). Secukinumab, an interleukin-17A inhibitor, has not been li…
Preview only. Read the full abstract at the source